RESTYLANE®, the original stabilized hyaluronic acid dermal filler, celebrates 25 years of achievement
– The NASHA® technology, which is still used today as the benchmark for dermal fillers, was pioneered by Galderma –
For more media materials, please visit:
TORONTO, Sept. 30, 2021 /CNW/ – At Galderma, the world’s largest independent dermatology company, we are proud to celebrate the 25th anniversary of the brand RESTYLANE® globally. The original non-animal stabilized hyaluronic acid dermal filler restores, enhances and refreshes for a youthful-looking appearance of the skin. Since launching in Europe in 1996, RESTYLANE has celebrated many milestones across the globe. This includes the first approval for use by Health Canada in 1999,1 and the U.S. Food and Drug Administration (FDA) in 2003.2
Over the years, the RESTYLANE portfolio has continued to deliver innovation. In 2015 the launch of the Optimal Balance Technology™ or OBT™ line of soft, flexible gels used in facial areas to support dynamic expressions and in 2017, RESTYLANE SKINBOOSTERS to help address the telltale signs of aging by improving the appearance, smoothness and elasticity of the skin.3,4,5 This approval marks a major success for the industry-standard filler. With over 30 ongoing pipeline projects in aesthetics alone, Galderma is seeking to enhance its diverse and broad portfolio of fillers to advance dermatology for every skin story in the future.
“I am incredibly proud to be celebrating the RESTYLANE 25th anniversary. Worldwide, and in Canada for the last 22 years, this brand has undoubtedly changed the lives of millions by helping them look and feel great. Galderma has the right technologies and capabilities to respond to evolving customer needs, and we will continue to build on our bright past to create a brilliant future!”
WENDY ADAMS, GENERAL MANAGER OF GALDERMA CANADA
The RESTYLANE portfolio offers the world’s most diverse range of fillers by using two complementary and patented gel technologies, the non-animal stabilized hyaluronic acid or NASHA® and OBT™.6 These technologies provide personalized, natural-looking results which deliver long-term satisfaction and leave individuals filled with confidence.5,7,8 RESTYLANE has become a trusted brand among health care professionals, with 50 million administered treatments worldwide, a major brand milestone achievement.9
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with health care professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.ca.
About Galderma’s RESTYLANE portfolio
RESTYLANE is the original non-animal stabilized hyaluronic acid filler with over 25 years of achievement and over 50 million treatments worldwide. NASHA® and OBT™ technologies make RESTYLANE the world’s most diverse range of fillers to deliver truly individualized results.6,10
The RESTYLANE portfolio of products in Canada includes: RESTYLANE LIDOCAINE, RESTYLANE LYFT LIDOCAINE, RESTYLANE SILK, RESTYLANE KYSSE, RESTYLANE VOLYME, RESTYLANE DEFYNE, RESTYLANE REFYNE, and RESTYLANE SKINBOOSTERS VITAL and VITAL LIGHT.
1 Data on File. Galderma Canada Inc.
2 FDA. Summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf2/P020023b.pdf Last accessed September 2021.
3 Restylane Skinboosters Vital Lidocaine Instructions for Use. Indicated in the lower cheek/jawline in the face and dorsal hands.
4 Restylane Skinboosters Vital Light Lidocaine Instructions for Use. Indicated in the lower cheek/jawline in the face and upper neck.
5 Philipp-Dormston WG, et al. Evaluating Perceived Naturalness of Facial Expression After Fillers to the Nasolabial Folds and Lower Face With Standardized Video and Photography. Dermatol Surg. 2018 Jun;44(6):826-832.
6 Data on file (MA-33939).
7 Talarico S et al. High Patient Satisfaction of a Hyaluronic Acid FillerProducing Enduring Full-Facial Volume Restoration: An18-Month Open Multicenter Study. Dermatol Surg. 2015 Dec;41(12):1361-9.
8 Cartier H et al. Perioral rejuvenation with a range of customized hyaluronic acid fillers: efficacy and safety over six months with a specific focus on the lips. J Drugs Dermatol 2012;11(1 Suppl):s17–26.
9 Data on file (MA-39680).
10 Öhrlund A. Poster presented at AMWC 2019.
SOURCE Galderma Canada
Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Agrigate Global takes no editorial responsibility for the same.